High density lipoprotein downregulates angiotensin II type 1 receptor and inhibits angiotensin II-induced cardiac hypertrophy

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 28-33

  Lin, Li ^a   Gong, Hui ^a   Ge, Jingyi ^a   Jiang, Guoliang ^a   Zhou, Ning ^a   Li, Lei ^a   Ye, Yong ^a   Zhang, Guoping ^a   Ge, Junbo ^a   Zou, Yunzeng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Angiotensin II; Angiotensin II type 1 receptor; Cardiac hypertrophy; High density lipoprotein

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; HIGH DENSITY LIPOPROTEIN; PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART HYPERTROPHY; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; LIPOPROTEINS, HDL; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1;

MUS; RATTUS;

EID: 78650907794     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.037     Document Type: Article

References (38)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left-ventricular mass in the framingham heart-study - reply. New England Journal of Medicine 1990, 323:1706-1707.
2. Yue H., Li W., Desnoyer R., Karnik S.S. Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovascular Research 2010, 85:90-99.
3. Ainscough J.F.X., Drinkhill M.J., Sedo A., Turner N.A., Brooke D.A., Balmforth A.J., Ball S.G. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovascular Research 2009, 81:592-600.
4. Oin Q.H., Brako L., Cheng L.H., Lewis W., Floyd D., Yang Q.L. Mice with cardiomyocyte-restricted smad4 deletion resist to angiotensin II induced cardiac hypertrophy. Circulation 2007, 116:1223.
5. Frank D., Kuhn C., Van Eickels M., Gehring D., Katus H.A., Frey N. Calsarcin-1 inhibits angiotensin-II induced cardiac hypertrophy in vivo and in vitro. European Journal of Heart Failure 2007, 6:44-45.
6. Hu C.M., Chen Y.H., Chiang M.T., Chau L.Y. Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo. Circulation 2004, 110:309-316.
7. De Smet H.R., Menadue M.F., Oliver J.R., Phillips P.A. Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats. Clinical and Experimental Pharmacology and Physiology 2003, 30:278-283.
8. Freund C., Schmidt-Ullrich R., Baurand A., Dunger S., Schneider W., Loser P., El-Jamali A., Dietz R., Scheidereit C., Bergmann M.W. Requirement of nuclear factor-kappa B in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005, 111:2319-2325.
9. Paradis P., Dali-Youcef N., Paradis F., Thibault G., Nemer M. Overexpression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Circulation 1999, 100:43.
10. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. Journal of Lipid Research 1995, 36:211-228.
11. Tall A.R. Plasma high-density lipoproteins - metabolism and relationship to atherogenesis. Journal of Clinical Investigation 1990, 86:379-384.
12. Clunn G., Hughes A., Schachter M. Endotoxin-lipoprotein hypothesis. Lancet 2000, 356:2097-2098.
13. Ansell B.J., Watson K.E., Fogelman A.M., Navab M., Fonarow G.C. High-density lipoprotein function - recent advances. Journal of the American College of Cardiology 2005, 46:1792-1798.
14. Kerola T., Nieminen T., Hartikainen S., Sulkava R., Vuolteenaho O., Kettunen R. High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population. Scandinavian Journal of Clinical & Laboratory Investigation 2009, 69:865-872.
15. de Simone G., Olsen M.H., Wachtell K., Hille D.A., Dahlof B., Ibsen H., Kjeldsen S.E., Lyle P.A., Devereux R.B. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the life study. Journal of Human Hypertension 2007, 21:625-632.
16. Anan F., Yonemochi H., Masaki T., Takahashi N., Fukunaga N., Teshima Y., Iwao T., Kaneda K., Eshima N., Saikawa T., Yoshimatsu H. High-density lipoprotein cholesterol and insulin resistance are independent and additive markers of left ventricular hypertrophy in essential hypertension. Hypertension Research 2007, 30:125-131.
17. Ikee R., Hamasaki Y., Oka M., Maesato K., Mano T., Moriya H., Ohtake T., Kobayashi S. High-density lipoprotein cholesterol and left ventricular mass index in peritoneal dialysis. Peritoneal Dialysis International 2008, 28:611-616.
18. Li D.Y., Saldeen T., Romeo F., Mehta J.L. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells - the potential role of transcription factor NF-kappa B. Circulation 2000, 102:1970-1976.
19. Singh B.M., Mehta J.L. Interactions between the renin-angiotensin system and dyslipidemia - relevance in the therapy of hypertension and coronary heart disease. Archives of Internal Medicine 2003, 163:1296-1304.
20. Nickenig G., Bohm M. Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia. European Journal of Medical Research 1997, 2:285-289.
21. Van Linthout S., Spillmann F., Lorenz M., Meloni M., Jacobs F., Egorova M., Stangl V., De Geest B., Schultheiss H.P., Tschope C. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 2009, 53:682-687.
22. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y.J., Akazawa H., Tateno K., Kayama Y., Harada M., Shimizu I., Asahara T., Hamada H., Tomita S., Molkentin J.D., Zou Y.Z., Komuro I. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
23. Bueno O.F., Molkentin J.D. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circulation Research 2002, 91:776-781.
24. Sadoshima J., Izumo S. Molecular characterization of angiotensin-II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts - critical role of the At(1) receptor subtype. Circulation Research 1993, 73:413-423.
25. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J., Vet C. Affairs high-density lipoprotein, gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New England Journal of Medicine 1999, 341:410-418.
26. Choudhury R.P., Rong J.X., Trogan E., Elmalem V.I., Dansky H.M., Breslow J.L., Witztum J.L., Fallon J.T., Fisher E.A. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arteriosclerosis Thrombosis and Vascular Biology 2004, 24:1904-1909.
27. Idzior-Walus B., Walus M., Foltyn A. High density lipoproteins and atherosclerosis. Przeglad Lekarski 2004, 61:1433-1435.
28. Lie J., Moerland M., van Gent T., van Haperen R., Scheek L., Sadeghi-Niaraki F., de Crom R., van Tol A. Sex differences in atherosclerosis in mice with elevated phospholipid transfer protein activity are related to decreased plasma high density lipoproteins and not to increased production of triglycerides. Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 2006, 1761:1070-1077.
29. Gomaraschi M., Calabresi L., Rossoni G., Iametti S., Franceschini G., Stonik J.A., Remaley A.T. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. Journal of Pharmacology and Experimental Therapeutics 2008, 324:776-783.
30. Keul P., Sattler K., Levkau B. HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Failure Reviews 2007, 12:301-306.
31. Theilmeier G., Schmidt C., Herrmann J., Keul P., Schafers M., Herrgott I., Mersmann J., Larmann J., Hermann S., Stypmann J., Schober O., Hildebrand R., Schulz R., Heusch G., Haude M., Lipinski K.V., Herzog C., Schmitz M., Erbel R., Chun J., Levkau B. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P(3) lysophospholipid receptor. Circulation 2006, 114:1403-1409.
32. Grigoryan S., Stepanyan A.A., Hazarapetyan L.G. Inhibitor of angiotensin II type I receptors eprosartan and antiodarone as a combined treatment of advanced heart failure and atrial fibrillation. European Journal of Heart Failure 2007, 6:151.
33. Yamamoto R., Akazawa H., Ito K., Toko H., Sano M., Yasuda N., Qin Y., Kudo Y., Sugaya T., Chien K.R., Komuro I. Angiotensin II type 1a receptor signals are involved in the progression of heart failure in MLP-deficient mice. Circulation Journal 2007, 71:1958-1964.
34. Baker K.M., Chernin M.I., Schreiber T., Sanghi S., Haiderzaidi S., Booz G.W., Dostal D.E., Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regulatory Peptides 2004, 120:5-13.
35. Anker S.D., Sharma R. The syndrome of cardiac cachexia. International Journal of Cardiology 2002, 85:51-66.
36. Velagaleti R.S., Massaro J., Vasan R.S., Robins S.J., Kannel W.B., Levy D. Relations of lipid concentrations to heart failure incidence the framingham heart study. Circulation 2009, 120:2345-2351.
37. Tolle M., Pawlak A., Schuchardt M., Kawamura A., Tietge U.J., Lorkowski S., Keul P., Assmann G., Chun J., Levkau B., van der Giet M., Nofer J.R. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arteriosclerosis Thrombosis and Vascular Biology 2008, 28:1542-1548.
38. Ohtsu H., Suzuki H., Nakashima H., Dhobale S., Frank G.D., Motley E.D., Eguchi S. Angiotensin II signal transduction through small GTP-binding proteins - mechanism and significance in vascular smooth muscle cells. Hypertension 2006, 48:534-540.